Long‐term response to afatinib in an elderly patient with uncommon epidermal growth factor receptor mutation‐positive lung adenocarcinoma

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are the standard treatment for patients with non‐small cell lung cancer (NSCLC) harboring EGFR mutations. Uncommon mutations, excluding exon 19 deletions and exon 21 L858R, comprise 7%–23% of EGFR mutation‐positive NSCLC. The treatme...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Thorac Cancer
Autori principali: Shijubou, Naoki, Sumi, Toshiyuki, Kamada, Koki, Sawai, Takeyuki, Yamada, Yuichi, Nakata, Hisashi, Mori, Yuji, Chiba, Hirofumi
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley & Sons Australia, Ltd 2021
Soggetti:
Case Reports
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7952783/
https://ncbi.nlm.nih.gov/pubmed/33533191
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13869
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi